Syndax Pharmaceuticals (SNDX) Expected to Announce Earnings on Thursday

Key Points

• Q1 2026 earnings due before market open on April 30: Analysts expect EPS of ($0.59) and revenue of $72.664 million, with an investor call scheduled for May 4 at 4:30 PM ET.
• Mixed recent results: Syndax missed EPS last quarter (‑$0.78 vs. a consensus of ‑$0.64) but reported revenue up 792.6% YoY to $68.73 million; analysts forecast about ‑$2 EPS for the current fiscal year and $0 for the next.
• Market sentiment and insider activity: SNDX trades near $21.39 with a $1.89B market cap and a consensus analyst target of $40.33 (average rating "Moderate Buy"), while insiders sold roughly 30,063 shares in recent filings.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.59) per share and revenue of $72.6640 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.14). Syndax Pharmaceuticals had a negative return on equity of 206.62% and a negative net margin of 165.37%.The firm had revenue of $68.73 million for the quarter, compared to the consensus estimate of $64.75 million. During the same quarter in the previous year, the business earned ($1.10) EPS. The firm's quarterly revenue was up 792.6% on a year-over-year basis. On average, analysts expect Syndax Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $21.39 on Monday. Syndax Pharmaceuticals has a 12 month low of $8.58 and a 12 month high of $25.59. The firm's 50 day moving average is $22.99 and its 200-day moving average is $20.27. The stock has a market capitalization of $1.89 billion, a PE ratio of -6.50 and a beta of 0.41. The company has a current ratio of 4.40, a quick ratio of 4.12 and a debt-to-equity ratio of 5.32.

Analyst Upgrades and Downgrades

SNDX has been the topic of several recent research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Syndax Pharmaceuticals in a report on Friday, March 27th. Jefferies Financial Group reaffirmed a "buy" rating and set a $40.00 target price (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. Stifel Nicolaus set a $45.00 price target on Syndax Pharmaceuticals in a research report on Friday, February 27th. Wall Street Zen upgraded Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, March 8th. Finally, JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an "overweight" rating in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $40.33.

Insider Buying and Selling

In related news, CEO Michael A. Metzger sold 17,159 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $360,853.77. Following the transaction, the chief executive officer directly owned 491,690 shares of the company's stock, valued at $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Keith A. Goldan sold 3,410 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the completion of the transaction, the chief financial officer directly owned 140,429 shares in the company, valued at $2,953,221.87. This trade represents a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,063 shares of company stock worth $628,332 over the last three months. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SNDX. Larson Financial Group LLC grew its position in Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company's stock valued at $45,000 after acquiring an additional 1,922 shares during the last quarter. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals in the third quarter valued at about $53,000. Smartleaf Asset Management LLC grew its position in Syndax Pharmaceuticals by 2,698.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company's stock valued at $55,000 after acquiring an additional 2,564 shares during the last quarter. Lazard Asset Management LLC bought a new position in Syndax Pharmaceuticals in the second quarter valued at about $66,000. Finally, Tower Research Capital LLC TRC grew its position in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company's stock valued at $79,000 after acquiring an additional 4,308 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax's research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company's lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.